Aptargroup (ATR) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Aptargroup (ATR) do?
Aptargroup Inc (ATR) is a U.S.-listed company in Healthcare (Medical Instruments & Supplies). What it does: Manufactures nasal spray devices, inhalers, lotion pumps, and aerosol valves for pharmaceutical and consumer goods companies. Designs and manufactures specialized drug delivery devices, spray pumps, and dispensing closures for global packaging. It is worth $8.90B on the market and sold $3.99B over the last year.
- Market cap
- $8.90B
- P/E ratio
- 34.0×
- Annual sales
- $3.99B
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Brief updated
- Nov 15, 2026
Brands and businesses behind ATR
- CSP Technologies: Manufactures active desiccant vials and protective polymer films sold directly to diagnostic kit and medication makers.
- Nanopharm: Provides formulation and laboratory testing services for inhaled and nasal drug products to pharmaceutical clients.
ATR’s flags, in plain English
Each flag is a number from Aptargroup’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 15, 2026.
Stupid Cash
Can pay this year's bills 1.5 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.
Low debt
Low debt, only 54% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.
Priced for Perfection
Priced at 34 times its yearly profit, so a lot of growth is already expected. The share price already assumes strong results, so news that is merely good can still send it down.
Questions about ATR
How big is Aptargroup?
Aptargroup’s market cap is $8.90B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $3.99B: what customers paid the company over the last year, before any costs.
What is ATR’s P/E ratio?
ATR’s P/E ratio is 34.0×. Investors pay about 34.0 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.
What could go wrong with ATR?
A substantial portion of high margin prescription revenue relies on a limited group of major pharmaceutical customers. That is one risk on Aptargroup’s card. Its first risk flag is Priced for Perfection, explained above. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Aptargroup’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. ATR’s filings on SEC.gov. The Margin Monkey is research, not advice.
